Lila Soto: Can I just start in the middle of a scene — is that okay? Because I've been trying to find the right way into this and the scene is the only thing that works.
Lila Soto: Tuesday morning. November 2026. Rheumatologist, busy practice, inbox open. And there are three separate FDA approval notices — not one, three — each for a drug or device that her patients have been asking about, in some cases for years. Gefurulimab, approved the 13th. Pimicotinib. The CGuard Prime stent from InspireMD. Three different conditions. Three mechanisms she's never had on her shelf before.
Iris Holm: Hold on — a stent is in a rheumatologist's inbox?
Lila Soto: Okay, fair — maybe she's forwarding that one to cardiology. But the point is the same week. The FDA cleared all three in the same week, and each one represents a genuinely new mechanism. That's not normal. And the question underneath all of it — the one I can't shake — is whether three new answers in a week is actually progress, or whether it just looks like progress until you try to use them.
Iris Holm: That's the whole thing, isn't it. Speed of approval versus clarity of choice.
Lila Soto: Exactly that — and we're going to pull all three apart.
Iris Holm: Pull on the gefurulimab thread — because the approval number lands and it immediately breaks the clean version of this story. PREVAIL trial. Week 26. 1.6-point improvement on MG-ADL over placebo.
Lila Soto: And she recognizes it. The rheumatologist. She's seen that number before.
Iris Holm: She's seen it six times. The whole approved class — eculizumab, Vyvgart, the rest — they span minus one to minus two-point-one. She's looking at drug seven and it fits perfectly inside the range of drugs one through six.
Lila Soto: So she can't actually tell if drug seven is better than drug one?
Iris Holm: Not from this data. No head-to-head trials exist — none, across any of the seven. The PREVAIL trial shows gefurulimab beats placebo. It doesn't show it beats eculizumab or efgartigimod. That comparison was never run.
Lila Soto: And eculizumab was the first C5 inhibitor she ever used for MG — so if gefurulimab is also a C5 inhibitor, same mechanism, overlapping numbers... I mean, what's actually different about it? Like, from where she's sitting.
Iris Holm: It's a nanobody instead of a full monoclonal antibody. Smaller molecule, different dosing — that's real. But here's the friction point: even if she wants to try it, she has to enroll in a REMS program first. Same meningococcal infection risk as the other C5 inhibitors, same administrative gate. So it's not just an evidence gap. There's paperwork standing between her and the choice.
Lila Soto: Oh — so the barrier isn't only intellectual. It's literally procedural.
Iris Holm: Right — and she's sitting there with no evidence compass and an enrollment form. That's the actual Tuesday morning.
Lila Soto: And that's the procedural wall — which, honestly, is the smaller version of the problem. Because pimicotinib is where it gets genuinely strange. So TGCT, tenosynovial giant cell tumor — the whole treatment logic there is CSF1R inhibition. That's the class. Pexidartinib pioneered it, 39% objective response rate. Then vimseltinib came in at 40% at week 25, better liver safety profile, and by early 2026 the academic literature had already declared it preferred first-line systemic therapy.
Iris Holm: So vimseltinib gets the crown.
Lila Soto: Gets the crown, yeah. And then — same week as these other two approvals — the FDA clears pimicotinib. Pimjetmi. Developed by Zhejiang Beta Pharma. CSF1R kinase inhibitor, full approval, symptomatic TGCT where surgery would carry high morbidity. Same class, same indication.
Iris Holm: With a higher response rate.
Lila Soto: Potentially — and I want to flag that word, because the 56% figure is out there, but I actually can't pin it cleanly to the pivotal trial data we have access to. It may be a different denominator, different cut. What I can say is the signal suggests higher than 40%. But the same early 2026 literature that crowned vimseltinib? It called pimicotinib 'emerging.' Not recommended. Emerging.
Iris Holm: So the literature calls it emerging, the FDA calls it approved. Those aren't the same statement.
Lila Soto: And no head-to-head trial reconciles them — none exists. I mean, picture a sarcoma specialist, sitting with a patient whose tumor is wrapped around a tendon sheath, surgery off the table. She has three CSF1R options now. Vimseltinib is what the guidelines implied. Pimicotinib might be more effective. She genuinely cannot know, because the approval and the literature are pointing in opposite directions and there's no data bridge between them.
Iris Holm: Does the FDA approval actually change what she prescribes, or does the literature just win by default?
Lila Soto: Honestly — I don't know, and I think that's the real answer. The approval creates legal access. It doesn't create clinical confidence. And the stent we haven't gotten to yet makes this whole pattern even sharper — that one was approved on 50 patients, answering a question the field wasn't actually asking.
Iris Holm: Fifty patients. That's the number. CGUARDIANS II — InspireMD's pivotal study for CGuard Prime — fifty high-surgical-risk patients, eleven U.S. sites. Zero strokes at thirty days. Zero deaths. Zero myocardial infarctions. The FDA approved the TCAR indication on November 12th, 2026, and that dataset is — look, it's the entire evidentiary record.
Lila Soto: Zero strokes in fifty people sounds extraordinary until you realize that's also just... one month of follow-up.
Iris Holm: And no comparator arm. No randomization against carotid endarterectomy, no transfemoral stenting group. Single arm. Thirty days. Done.
Lila Soto: So we approved it to solve a problem that wasn't — I mean, was short-term stroke risk actually the open question in TCAR?
Iris Holm: No. The field's actual unsolved problems are durability and restenosis. What happens to the stent over years, not over a month. CGUARDIANS II doesn't touch either of those. The trial answered a question the field had basically already moved past.
Lila Soto: Oh — so perfectly clean data, completely wrong question.
Iris Holm: And the commercial consequence of that approval is — frankly, this is the part that doesn't sit quietly — the expanded TCAR indication covers more than thirty-five thousand annual procedures in the U.S. InspireMD roughly doubled its addressable market. On fifty patients and thirty days of follow-up. No control group.
Lila Soto: I keep trying to find the version of this where that's fine. And I think — mm, the FDA's logic isn't wrong exactly, it's just that unmet need plus a clean short-term signal has become sufficient. Same pattern as the other two approvals this week. Urgency is doing the work that evidence hasn't finished doing.
Iris Holm: Right — but the part that doesn't fit is that the unmet need in TCAR isn't stroke prevention at thirty days. It's what happens at year two or three when nobody's watching. The approval closes a question. It doesn't close the right question.
Lila Soto: So she closes the inbox. The rheumatologist. Three tabs still open — gefurulimab, pimicotinib, the CGuard Prime notice she's forwarding to someone else. And she has more options than she had Monday. That part is real. I mean, genuinely real — patients who had no systemic therapy for TGCT now have three CSF1R inhibitors. Patients who'd exhausted broad immunosuppression for MG have a seventh mechanism on the shelf. That happened.
Iris Holm: And none of the three was tested against what already exists. No head-to-head. Not one.
Lila Soto: Which means the evidence that actually ranks them — the thing that would tell her which of the seven MG biologics to reach for first, or whether pimicotinib is genuinely better than vimseltinib at something that matters — that evidence is going to come from registries. Observational data. The real world. Not from PREVAIL, not from CGUARDIANS II. Eighteen to twenty-four months from now, probably.
Iris Holm: The next phase four trial is just — Tuesday morning. Every Tuesday morning for the next two years. Whether anyone calls it that.
Lila Soto: Yeah. Hm. That's kind of exactly it. She walked in with an inbox and walked out with an experiment she didn't consent to run.
Iris Holm: Good conversation. Genuinely.